This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Baxter Collaborates With Mayo Clinic to Open Renal Care Center
by Zacks Equity Research
Per the agreement, Baxter (BAX) and Mayo Clinic researchers to form an outpatient clinic for kidney disease management, home dialysis and in-center dialysis services.
Baxter (BAX) Collaborates With USC CBC to Digitize Healthcare
by Zacks Equity Research
Baxter's (BAX) efforts to digitize healthcare solutions are likely to fortify its foothold in the highly competitive MedTech industry.
Stock Market News For Sep 27, 2018
by Zacks Equity Research
Wall Street ended lower on Wednesday following quarter point interest rate hike by the Fed.
Baxter's (BAX) ALTAPORE Bioactive Bone Graft Gets FDA Nod
by Zacks Equity Research
Baxter's (BAX) offers a broad spectrum of surgical products, including bone grafts and substitutes that see lucrative market prospects.
Accuray's CyberKnife Manages Prostate Cancer Effectively
by Zacks Equity Research
Accuray's (ARAY) flagship CyberKnife is the only robotic radiotherapy system.
Here's Why You Should Buy Baxter International (BAX) Now
by Zacks Equity Research
Baxter's (BAX) raised guidance for 2018 and a series of approvals make it a promising investment pick.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech
Stock Market News For Sept 7, 2018
by Zacks Equity Research
U.S. stock market closed mostly lower on Thursday as softness in tech sector, trade war concerns and fear of contagion from some emerging markets problems have rattled investor confidence
Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod
by Zacks Equity Research
The latest FDA approval for Baxter's (BAX) Actifuse Flow bone graft is likely to boost its Advanced Surgery segment.
Kidney Care Demand Shoots Up in US: 3 Stocks Likely to Gain
by Sreyoshi Mukherjee
As the U.S. dialysis industry has been garnering huge profits for decades, some dialysis stocks are worth a look.
The Zacks Analyst Blog Highlights: JPMorgan, Altria, Charter Communications, Baxter and lululemon
by Tirthankar Chakraborty
The Zacks Analyst Blog Highlights: JPMorgan, Altria, Charter Communications, Baxter and lululemon
Here's Why You Should Hold On to Baxter (BAX) Stock Now
by Zacks Equity Research
Baxter's (BAX) cyclophosphamide performance continues to remain dismal. Nevertheless, the company witnesses positive tidings of other products on the regulatory front.
Top Research Reports for JPMorgan, Altria & Charter Communications
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Altria (MO) and Charter Communications (CHTR).
Mallinckrodt (MNK) Beats on Q2 Earnings and Sales, Ups View
by Zacks Equity Research
Mallinckrodt (MNK) surges following earnings and sales beat in the second quarter. Increase in annual guidance is impressive as well.
Abiomed Gets CDSCO Nod for Impella Heart Pumps in India
by Zacks Equity Research
Abiomed's (ABMD) Impella gets regulatory approval in India; prospects in APAC look upbeat.
Baxter (BAX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Baxter (BAX) gains on the back of its core Renal Care segment in Q2; solid international sales encourage.
Baxter (BAX) Beats on Q2 Earnings; Sales Meet Estimates
by Zacks Equity Research
Baxter (BAX) gains from solid segmental performance in Q2.
Baxter International (BAX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 8.45% and 0.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Earnings Lineup for Jul 26: BAX, EW & More
by Zacks Equity Research
Streak of regulatory developments and deep R&D focus are likely to drive the Medical Product industry this earnings season. Here we take a quick look at four Medical Product majors that are going to release earnings results.
Can Overall Growth Drive ResMed's (RMD) Q4 Earnings?
by Zacks Equity Research
ResMed (RMD) is likely to keep its winning streak alive with a gain from strong performances on the domestic as well as global front in Q4.
Can CAG Growth Continue to Aid IDEXX (IDXX) in Q2 Earnings?
by Zacks Equity Research
IDEXX (IDXX) is enhancing its commercial capabilities in the United States to maintain recurring revenue growth at CAG Diagnostics.
Can Solid Overall Growth Drive Illumina's (ILMN) Q2 Earnings?
by Zacks Equity Research
Illumina (ILMN) to gain from strong revenues at the Product, Service and other segments in Q2.
Molecular Diagnostics to Aid Hologic's (HOLX) Q3 Earnings
by Zacks Equity Research
Strength in the Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) molecular diagnostics in Q3.
What's in Store for GNC Holdings (GNC) This Earnings Season?
by Zacks Equity Research
GNC Holdings' (GNC) revenues are likely to decline on a year-over-year basis, owing to weakness in U.S. & Canada segments in Q2.
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
by Zacks Equity Research
We are upbeat about Abbott's (ABT) synergies from Alere buyout in the form of solid Rapid Diagnostics revenues. Emerging market performance has been promising.